Company Profile for Highland Therapeutics Inc.

--()--Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS™, to optimize the delivery of previously approved drug products. The Company's lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS™ is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.

Company:

  Highland Therapeutics Inc.
 

Headquarters Address:

MaRS Centre, South Tower
101 College St., Suite 310
Toronto, ON M5G 1L7
Canada
 

Main Telephone:

647-260-7875
 

Website:

www.highlandtherapeutics.com

 

Type of Organization:

Private
 

Industry:

Pharmaceutical

 

Key Executives:

CFO: Nelson Isabel

 

Investor Relations

Contact:

Nelson Isabel

Phone:

647-694-1966 x177

Email:

nelson@highlandtherapeutics.com